Lung Cancer Focus
VisionGate is focused on lung cancer – the world’s deadliest cancer
According to the American Cancer Society, in the U.S. alone, more than 225,000 new cases of lung cancer will be diagnosed in 2017 and nearly 156,000 Americans will die of the disease. Lung cancer is by far the leading cause of cancer death among both men and women; about 1 out of 4 cancer deaths are from lung cancer. Each year, more people die of lung cancer than of colon, breast, and prostate cancers combined.
At VisionGate, our focus is on developing new diagnostics and therapeutics that improve the early detection and treatment of patients with lung cancer, lung dysplasia, indeterminate pulmonary nodules (IPN), and those at high risk for lung cancer. Our mission is to save lives through early disease detection and treatment and we hope to change the paradigm for early detection of lung cancer and lung dysplasia.
Towards that end, VisionGate is developing the LuCED® lung test to aid physicians in detecting and treating lung cancer and lung dysplasia. We are also advancing in clinical research of our pharmaceutical treatment iloprost, an investigative oral prostacyclin analog. Our aim is to introduce a potential first-in-class class therapeutic treatment for lung dysplasia and a chemoprevention agent for lung cancer.
Lung cancer screening reduces mortality from lung cancer
The National Lung Screening Trial (NLST) was a National Cancer Institute (NCI) supported randomized controlled clinical trial of screening tests for lung cancer. Over 53,000 current or former heavy smokers, ages 55 to 74 and at high risk of lung cancer, joined the NLST at study centers across the United States. Participants were randomly assigned to two study arms in equal proportions comparing two ways of detecting lung cancer: low-dose computed tomography (CT); and standard chest X-ray.
On June 29, 2011, the results were published online in the New England Journal of Medicine. The results revealed that screening with the use of low-dose CT provided an opportunity to treat patients earlier, resulting in a 20% decrease in the number of deaths from lung cancer.
The NLST results have prompted the United States Preventive Services Task Force (USPSTF) to issue the first recommendation in favor of lung cancer screening. However, the study helped identify potential problems associated with lung cancer screening using low dose-CT (LDCT), notably, the high proportion of individuals with lung nodules who ended up not having cancer (i.e., false positives). A great concern is that this may lead to unnecessary invasive diagnostic procedures. VisionGate’s LuCED® lung test aims to improve upon the efficiency of lung cancer screening with LDCT.
There is high unmet medical need for better diagnostic tests and new treatments
The NSLT has proven the benefit of lung cancer screening with low-dose CT. Now, VisionGate intends to build on and improve available diagnostic tools and techniques. We are focused on improving the accuracy and the ease of lung cancer screening and thereby greatly expand the acceptance of screening and the rate of early detection and treatment of lung cancer and lung dysplasia.